Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension
Brain · 2026
DOI: 10.1093/brain/awag126 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Brain, 2026. Verfasst von Andreas Yiangou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Pseudotumor Cerebri, Headache. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association of British Neurologists, Guarantors of Brain, Danish National Research Foundation.
Abstract (Originalsprache)
Calcitonin gene-related peptide (CGRP) is a key mediator in migraine pathophysiology. Idiopathic intracranial hypertension (IIH) headache phenotype is now understood to be typically migraine-like, but it is unclear whether CGRP directly provokes IIH headaches or alters intracranial pressure (ICP) dynamics. We conducted a randomized, double-blind, placebo-controlled, two-way crossover trial to address this. Twenty women with IIH and no prior migraine were randomly assigned to receive a 20-min continuous intravenous infusion of CGRP (1.5 μg/min) or placebo (isotonic saline). The primary outcome was the difference in the proportion of participants who developed a provoked headache attack between CGRP and placebo during the 12 h observation after infusion. Secondary outcomes included the area under the curve (AUC) for headache intensity from −10 min to 12 h, the timing and duration of headache features, and baseline-adjusted changes for vital signs, cerebrovascular haemodynamics and ICP. Seventeen participants with mean age (standard deviation) 26.7 (6.4) years completed both visits. Twelve (71%) participants developed a typical IIH headache attack with migraine-like features after CGRP compared with three (18%) after placebo (risk difference 53%; 95% confidence interval, 26–79; P = 0.004). The AUC−10min-12h for headache intensity was higher after CGRP than after placebo (P = 0.016). The mean ICP remained unchanged, whereas ICP amplitude increased significantly after CGRP (P = 0.005). Vital signs and cerebrovascular haemodynamics AUC−10min-90min were significantly altered after CGRP [increased: heart rate (P < 0.001), tissue oxygenation index (P = 0.041), and oxygenated haemoglobin (P < 0.001); decreased: mean arterial pressure (P = 0.010) and middle cerebral artery blood velocity (P = 0.006)]. CGRP reliably provoked typical IIH headache attacks (which have migraine-like features) and increased ICP pulse amplitude, as a measure of intracranial compliance, without altering mean pressure. These findings provide mechanistic support for CGRP involvement in headache attributed to IIH and justify prospective evaluation of CGRP pathway blockade in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK.
- Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK.
- Department of Neurology, Centre for Discoveries in Migraine, Danish Headache Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen 2600, Denmark.
- Ophthalmology Department, Queen's University, Kingston, Ontario K7L 4V7, Canada.
- Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre, Stanford Hall LE12 5QW, UK.
- School of Biomedical Sciences, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK.
ORCID-Profile: Andreas Yiangou, Susan P Mollan, Mark Thaller, James L Mitchell, Georgios Tsermoulas, Lisa J Hill, Samuel J E Lucas, Alexandra J Sinclair
Förderung
- Association of British Neurologists
- Guarantors of Brain
- Danish National Research Foundation
- Novo Nordisk Foundation
- Novartis
- Lundbeck Foundation
- Wellcome Trust
- Lundbeck A/S
Zitieren
APA
Yiangou, A., Do, T. P., Mollan, S. P., Thaller, M., Mitchell, J. L., Mugo, C. W., Tsermoulas, G., Hill, L. J., Lucas, S. J. E., Ashina, M., & Sinclair, A. J. (2026). Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension. Brain. https://doi.org/10.1093/brain/awag126
Vancouver
Yiangou A, Do TP, Mollan SP, Thaller M, Mitchell JL, Mugo CW, et al. Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension. Brain. 2026. doi:10.1093/brain/awag126
BibTeX
@article{Yiangou2026,
author = {Yiangou, Andreas and Do, Thien Phu and Mollan, Susan P and Thaller, Mark and Mitchell, James L and Mugo, Caroline W and Tsermoulas, Georgios and Hill, Lisa J and Lucas, Samuel J E and Ashina, Messoud and Sinclair, Alexandra J},
title = {Calcitonin gene-related peptide induces headache attacks in people with idiopathic intracranial hypertension},
journal = {Brain},
year = {2026},
doi = {10.1093/brain/awag126}
}
EUVIMED